Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy

被引:38
|
作者
Sainz-Esteban, Aurora [3 ]
Prasad, Vikas [1 ,2 ]
Schuchardt, Christiane [1 ,2 ]
Zachert, Carolin [1 ,2 ]
Manuel Carril, Jose [3 ]
Baum, Richard P. [1 ,2 ]
机构
[1] Zent Klin Bad Berka, Dept Nucl Med, D-99437 Bad Berka, Germany
[2] Zent Klin Bad Berka, Ctr PET CT, D-99437 Bad Berka, Germany
[3] Hosp Univ Marques de Valdecilla, Dept Nucl Med, Santander, Spain
关键词
Lu-177-DOTA-TATE; Dosimetry scan; Ga-68-DOTA-TATE; Neuroendocrine tumour; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; BIODISTRIBUTION; SCINTIGRAPHY; AFFINITY; GA-68;
D O I
10.1007/s00259-011-2003-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The aim of the study was to compare sequential Lu-177-DOTA-TATE planar scans (Lu-177-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic Ga-68-DOTA-TATE positron emission tomography (PET)/CT (Ga-68-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods. Methods A total of 44 patients (59 +/- 11 years old) with biopsy-proven NET underwent Ga-68-DOTA-TATE and Lu-177-DOTA-TATE imaging within 7.9 +/- 7.5 days between the two examinations. Lu-177-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on Lu-177-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on Ga-68-DOTA-TATE studies obtained before PRRT. Results A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were Ga-68-DOTA-TATE positive and Lu-177-DOTA-TATE negative, whereas 9 were Ga-68-DOTA-TATE negative and Lu-177-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for Lu-177-DOTA-TATE as compared to Ga-68-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h) Lu-177-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (n=77; mean size 3.8 cm) were significantly larger than discordant lesions (n=38; mean size 1.6 cm) (p<0.05). No such significance was found for differences in maximum standardized uptake value (SUVmax). However, concordant liver lesions with a score from 1 to 3 in the 72-h (177)LuDOTA- TATE scan had a lower SUVmax (n=23; mean 10.9) than those metastases with a score of 4 (n=97; mean SUVmax 18) (p<0.05). Conclusion Although Lu-177-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for thedetection of metastases, they failed to pick up 9% of lesions seen on the Ga-68-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 50 条
  • [31] Comparison of radiation dosimetry of [68Ga]Ga-DOTA-TOC and [68Ga]Ga-DOTA-TATE in patients affected by neuroendocrine tumours
    Velikyan, Irina
    Sandstrom, Mattias
    Garske, Ulrike
    Sorensen, Jens
    Eriksson, Barbro
    Granberg, Dan
    Sundin, Anders
    Lubberink, Mark
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 : S270 - S270
  • [32] Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
    Gadens Zamboni, Camila
    Dundar, Ayca
    Jain, Sanchay
    Kruzer, Marc
    Loeffler, Bradley T.
    Graves, Stephen A.
    Pollard, Janet H.
    Mott, Sarah L.
    Dillon, Joseph S.
    Graham, Michael M.
    Menda, Yusuf
    Shariftabrizi, Ahmad
    EJNMMI REPORTS, 2024, 8 (01)
  • [33] Role of PET/CT with 68Ga-DOTA-TATE in the evaluation of patients with medullary thyroid carcinoma
    Silvera, Enzo
    Banchero, Agustina
    Ortega, Renee
    Savio, Eduardo
    Alonso, Omar
    Duarte, Pablo
    Gambini, Juan
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [34] The Impact of Total Variation Regularized Expectation Maximization Reconstruction on 68Ga-DOTA-TATE PET/CT Images in Patients With Neuroendocrine Tumor
    Liu, Lin
    Liu, Hanxiang
    Xu, Shijie
    Zhang, Shumao
    Tao, Yi
    Mok, Greta S. P.
    Chen, Yue
    FRONTIERS IN MEDICINE, 2022, 9
  • [35] PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine Differentiation in Patients With Castrate-Resistant Prostate Cancer
    Gofrit, Ofer Nathan
    Frank, Stephen
    Meirovitz, Amichay
    Nechushtan, Hovav
    Orevi, Marina
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (01) : 1 - 6
  • [36] Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Simone Krebs
    Joseph A. O’Donoghue
    Evan Biegel
    Bradley J. Beattie
    Diane Reidy
    Serge K. Lyashchenko
    Jason S. Lewis
    Lisa Bodei
    Wolfgang A. Weber
    Neeta Pandit-Taskar
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 3047 - 3057
  • [37] Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Krebs, Simone
    O'Donoghue, Joseph A.
    Biegel, Evan
    Beattie, Bradley J.
    Reidy, Diane
    Lyashchenko, Serge K.
    Lewis, Jason S.
    Bodei, Lisa
    Weber, Wolfgang A.
    Pandit-Taskar, Neeta
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (13) : 3047 - 3057
  • [38] Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours
    Yilmaz, S.
    Demirci, E.
    Ocak, M.
    Aygun, A.
    Halac, M.
    Sager, S.
    Kabasakal, L.
    Kanmaz, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S588 - S588
  • [39] Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours
    Yilmaz, Sabire
    Demirci, Emre
    Ocak, Meltem
    Aygun, Aslan
    Halac, Metin
    Sager, Sait
    Kabasakal, Levent
    Kanmaz, Bedii
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [40] Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours
    Yilmaz, S.
    Demirci, E.
    Ocak, M.
    Gunes, B.
    Kabasakal, L.
    Halac, M.
    Araman, A.
    Decristoforo, C.
    Uslu, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S382 - S382